Neutralizing antibody responses to SARS-CoV-2 Omicron variants: Post six months following two-dose & three-dose vaccination of ChAdOx1 nCoV-19 or BBV152

• DOI: 10.4103/ijmr.ijmr_948_23
• Publication Date: 2024-04-09T09:32:19Z
• Authors: Pragya D. Yadav; Viren Sardana; Gururaj Rao Deshp...; Pradnya V. Shinde; Jeromie Wesley Vi...; Leyanna S. George; Gajanan N. Sapkal; Deepak Y. Patil; Rima R. Sahay; Anita M. Shete; Madhavi Joshi; Manoj Murhekar; Sheela Godbole; Nivedita Gupta; Satyartha Prakash; Mamta Rathore; Rajat Ujjainiya; Ajay Pratap Singh; Aastha Mishra; Debasis Dash; Kumardeep Chaudhary; Shantanu Sengupta
• Keywords: Immune escape; Infectivity

The Omicron sub-lineages are known to have higher infectivity, immune escape and lower virulence. During December 2022 - January 2023 March April 2023, India witnessed increased SARS-CoV-2 infections, mostly due newer sub-lineages. With this unprecedented rise in cases, we assessed the neutralization potential of individuals vaccinated with ChAdOx1 nCoV (Covishield) BBV152 (Covaxin) against emerging